Allscripts (MDRX) Tops Q1 EPS by 4c; Provides FY21 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
JPMorgan Resumes Allscripts (MDRX) at Underweight
April 29, 2021 6:17 AM EDTJPMorgan analyst Anne Samuel resumes coverage on Allscripts (NASDAQ: MDRX) with a Underweight rating and a price target of $15.00.
For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.
Shares of Allscripts closed at $15.83 yesterday.
... More